Test Price
2,800 AED✅ Home Collection Available
CFHR3 Gene Hemolytic Uremic Syndrome Genetic Test in UAE | 2800 AED | DHA Approved
Executive Summary & Core Metrics
Executive Summary: CFHR3 NGS test delivers definitive molecular diagnosis for atypical Hemolytic Uremic Syndrome (aHUS) with >99.9% sensitivity, compliant with UAE Federal Decree-Law No. 45 of 2021 (PDPL) and Federal Law No. 2 of 2019 on health ICT. VIP home phlebotomy and ISO‑certified cold‑chain logistics ensure patient comfort.
- Accuracy Guarantee: >99.9% diagnostic sensitivity validated via ISO 9001:2015 accredited NGS platform (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Hospital‑grade home collection through temperature‑controlled courier; VIP mobile phlebotomy daily 8 AM–11 PM.
- Clinical Guidance: Complimentary post‑test telephonic correlation session with a DHA‑licensed genetic consultant.
- Insurance: Direct billing verification & appointment scheduling via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The CFHR3 gene assay utilises Next‑Generation Sequencing (NGS) to interrogate all coding exons and flanking intronic regions, identifying pathogenic and likely pathogenic variants causative of aHUS. This complement‑mediated thrombotic microangiopathy requires early genetic confirmation for optimal management with eculizumab and family counselling.
| Feature | Our CFHR3 NGS Test | Closest Regional Alternative |
|---|---|---|
| Methodology | Comprehensive NGS (all exons ± flanking regions) | Sanger sequencing of selected hot‑spots |
| Diagnostic Yield | >99.9% sensitivity for known and novel mutations | 70–85% – misses rare novel variants |
| Turn‑Around Time | 3–4 Weeks (ISO 9001:2015 accredited lab) | 5–7 Weeks |
| Pre‑Test Support | Mandatory genetic counselling session with pedigree charting | Often omitted |
| Regulatory Compliance | Full adherence to UAE PDPL & Federal Law No. 2 of 2019 | Variable |
Physician Insight & Safety Protocols
“As a clinical geneticist, I understand the anxiety aHUS genetic testing can bring. This assay provides actionable variants to guide eculizumab therapy, inform family screening, and anticipate renal outcomes – always integrated with clinical assessment and complement activity profiles. Never alter treatment solely on genetic findings.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
⚠ CRITICAL: Do Not Alter Prescribed Therapies
Do not discontinue or modify immunosuppressants, anticoagulants, or complement inhibitors (e.g., eculizumab) without consulting your treating physician. Results of this test are for clinical correlation only.
Patient Safety & Exclusion Criteria
- Exclusion: Minors without legal guardian consent (per UAE Federal Law No. 2 of 2019 on health ICT); patients who have not completed mandatory pre‑test genetic counselling.
- Emergency Red Flags – Seek immediate care if: Sudden severe decrease in urine output, unexplained bruising or bleeding, severe pallor, confusion, seizures, or chest pain.
Patient FAQ & Clinical Guidance
1. What does the CFHR3 gene test detect?
Quick Answer: CFHR3 NGS test detects genetic mutations causing atypical HUS, a serious renal and hematologic disease.
The test sequences the entire CFHR3 gene to identify pathogenic variants that disrupt complement regulation. These mutations are responsible for uncontrolled complement activation, microvascular thrombosis, and kidney failure. Early detection enables targeted therapy and family planning.
2. How long until I get results and what is the cost?
Quick Answer: Results are available in 3–4 weeks at a cost of 2,800 AED, with DHA oversight.
After sample collection (blood, extracted DNA, or FTA card), our ISO‑accredited NGS platform analyses the gene. The final report includes variant classification, clinical interpretation, and management recommendations.
3. Can I have a home sample collection and what do I need to prepare?
Quick Answer: Yes, DHA‑licensed home phlebotomy is available daily 8 AM–11 PM, including pre‑test genetic counselling.
A certified phlebotomist visits your location; samples are transported under validated cold‑chain conditions. Mandatory pre‑test counselling (phone/video) documents family history and explains implications of results. Acceptable specimens: peripheral blood, extracted DNA, or FTA card spot.
UAE Regulatory & Data Privacy Adherence
Data Protection & Clinical Compliance
- Personal Data Protection: Fully compliant with Federal Decree-Law No. 45 of 2021 (PDPL) – patient genetic data is encrypted, pseudonymised, and used only for diagnostic purposes.
- Health Information Technology: Adheres to Federal Law No. 2 of 2019 concerning Use of ICT in Health Fields, ensuring secure electronic health records and consent management.
- Medical Liability: Genetic counselling and testing follow Federal Decree-Law No. 4 of 2016 on Medical Liability, guaranteeing informed consent and clinical accountability.
- Accreditation: Laboratory is ISO 9001:2015 certified (INT/EGQ/2509DA/3139) and DHA‑licensed (Facility #1143).
Clinical & Logistical Metadata
| Test Name | CFHR3 Gene Hemolytic Uremic Syndrome NGS Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Blood (EDTA), Extracted DNA, or Dried Blood Spot (FTA card) |
| Methodology Used | Next‑Generation Sequencing (NGS) – full coding exons + flanking introns |
| ICD-10-CM Code | D59.3 (Atypical hemolytic uremic syndrome) |
| LOINC Code | 81439-3 (CFHR3 gene mutation analysis in Blood or Tissue by NGS) |
| DHA Facility License & Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians